Invokana Amputation Lawsuit 2026: Eligibility, MDL Status, and Settlement Value Guide

My read on Invokana cases is simple: the lawsuit either stands or falls on two pieces of paper — an amputation surgical record or a DKA hospitalization record. Everything else is negotiation.

If you’re searching for this because someone in your family lost a toe, a foot, or part of a leg after years on Invokana, or ended up in the ICU with ketoacidosis that nobody expected, you’re not alone, and you’re not necessarily too late. Here’s what actually matters in 2026.

---

What Is Invokana, and Why Did It Become a Lawsuit Magnet?

Invokana (canagliflozin) is a type 2 diabetes medication made by Janssen Pharmaceuticals, part of Johnson & Johnson. Approved in 2013, it was among the first SGLT2 inhibitors on the U.S. market — a drug class that works by blocking glucose reabsorption in the kidneys, flushing excess sugar out through urine instead.

Two safety signals turned this from a promising diabetes drug into a mass tort target.

The DKA warning (2015). The FDA flagged the entire SGLT2 class — Invokana, Farxiga, Jardiance, Steglatro — for diabetic ketoacidosis risk. What made this particularly dangerous is that some patients developed “euglycemic DKA” — ketoacidosis with near-normal blood sugar readings, which doctors and patients alike weren’t trained to suspect. Diagnosis got delayed in a meaningful number of cases.

The amputation black box warning (2017). This one hit Invokana specifically, not the whole class. Data from the CANVAS and CANVAS-R clinical trials showed patients on canagliflozin faced roughly double the risk of leg and foot amputation compared to placebo. The FDA required Invokana and Invokamet to carry the strongest warning label the agency issues.

Plaintiffs argue Janssen knew or should have known about the amputation risk earlier and delayed adequate warnings, during which time patients underwent amputations that earlier warnings might have helped prevent. Janssen’s defense leans heavily on the fact that diabetes itself is an independent risk factor for vascular disease and amputation — a point that matters a lot for case strength, which I’ll get to below.

---

Which SGLT2 Drug Did You Actually Take? It Changes Everything

This is where a lot of people get tripped up. Not every SGLT2 inhibitor carries the same legal exposure.

Drug (generic)	Manufacturer	Amputation Black Box Warning	Litigation Status
Invokana (canagliflozin)	Janssen (J&J)	Yes (2017)	MDL 2750; large private settlement in 2021
Farxiga (dapagliflozin)	AstraZeneca	No	No amputation mass tort; class-wide DKA warning applies
Jardiance (empagliflozin)	Boehringer Ingelheim / Eli Lilly	No	No amputation mass tort; class-wide DKA warning applies
Steglatro (ertugliflozin)	Pfizer / Merck	No	No amputation mass tort

If your claim is amputation-based, you generally need to have taken Invokana or Invokamet specifically, because the black box warning that anchors the legal theory doesn’t exist for the other drugs. DKA claims are a different story — since that warning applies class-wide, a DKA hospitalization linked to any SGLT2 inhibitor is worth reviewing with an attorney, even if the drug wasn’t Invokana.

---

Which Injuries Actually Qualify

Two categories carry weight in this litigation.

Injury category	What it looks like	Evidence you’ll need
Lower-limb amputation	Toe, foot, below-the-knee (BKA), above-the-knee (AKA)	Surgical records, physician’s stated reason for amputation, Invokana prescription/fill history
Diabetic ketoacidosis (DKA)	ER visit or hospitalization for metabolic acidosis, including euglycemic DKA	Blood ketone and pH lab values, admission records, timing relative to drug use
Secondary DKA harm	Coma, acute kidney injury, in rare cases death	Death certificate or renal function testing; estate representative documentation for wrongful death claims

“My blood sugar was hard to control” or “my wound healed slowly” isn’t enough on its own. What moves a case forward is a documented amputation procedure or a DKA-coded hospital admission. Those two documents are the foundation everything else is built on.

Having pre-existing peripheral artery disease (PAD) or diabetic neuropathy doesn’t disqualify you, but it raises the bar. Defense counsel will argue your amputation was the natural progression of underlying disease, not the drug. What helps: a documented acceleration in vascular decline that lines up with when you started taking Invokana, backed by your treating physician’s notes.

---

Where Does MDL 2750 Stand Right Now?

Federal cases scattered across the country were consolidated into MDL 2750 (In re: Invokana Products Liability Litigation) in the District of New Jersey back in late 2016. An MDL doesn’t merge cases into one trial — it consolidates the repetitive pretrial work (discovery, expert witness admissibility rulings) before a single judge so hundreds of cases aren’t relitigating the same ground.

In early 2021, Janssen reached a private settlement, reported by legal media at roughly $300 million, to resolve a large portion of the pending inventory. That figure covered the settlement fund as a whole, allocated by injury tier — not an identical check to every plaintiff.

Here’s the part people miss: that settlement didn’t shut the door. Patients diagnosed after the program closed, plaintiffs who didn’t qualify for it, and anyone whose statute of limitations is still running can file individual suits or pursue remaining proceedings. New cases keep coming in, though the pattern after a large early settlement tends to shift toward smaller individual negotiations rather than another mega-settlement.

---

How Is Settlement Value Actually Calculated?

There’s no public payout chart, and I’d treat any ad quoting a specific number as a warning sign rather than a promise. That said, the factors that drive value in this kind of mass tort are fairly consistent across firms.

Valuation factor	Effect on settlement value
Amputation level	Toe < foot < below-knee (BKA) < above-knee (AKA), generally rising in that order
Age / lost earning capacity	Working-age plaintiffs with documented wage loss tend to see higher valuations
Pre-existing vascular disease	Stronger PAD/neuropathy history increases causation disputes, potentially weakening leverage
Duration and dose of use	Longer, higher-dose use histories generally strengthen causation arguments
Additional surgery / prosthetics	Revision surgeries, prosthetic fitting, and rehab needs increase value
DKA severity	Coma, organ damage, or death is valued well above a straightforward hospital stay

Above-knee amputations with permanent disability are consistently valued higher than toe amputations. On the flip side, plaintiffs with severe pre-existing vascular disease often see lower initial offers because causation is contested harder — which is exactly where an attorney with access to strong vascular surgery and endocrinology expert witnesses earns their fee.

---

Three Real-World Scenarios: Where Do You Fit?

Scenario A: Clean causation, no prior vascular disease. A patient in their 50s took Invokana for over two years, developed a minor foot wound that wouldn’t heal, and eventually lost the foot. No PAD diagnosis existed beforehand, and the timeline between starting the drug and the injury is clear. Cases like this tend to have simpler causation fights and stronger negotiating positions.

Scenario B: Pre-existing diabetic vascular disease. A patient already diagnosed with PAD before starting Invokana, with a history of regular vascular surgery follow-ups. Defense will argue the amputation was inevitable regardless of the drug. The case isn’t dead, but it needs medical documentation showing the vascular decline accelerated meaningfully after starting the drug — not just that it existed before.

Scenario C: Wrongful death from DKA. A spouse or parent developed euglycemic DKA that went undiagnosed until it was too late, and died as a result. Surviving family members can bring a wrongful death claim. The critical documents here are the estate representative’s legal standing, the death certificate, and ER lab values from the initial presentation. It’s the hardest scenario emotionally, but eligibility tends to be relatively clear-cut on paper.

All three share the same requirement: a documented diagnosis plus a documented usage history. The murkier your case looks on paper, the more it pays to be fully transparent with your attorney about your entire medical history upfront.

---

What Evidence Should You Gather Before Your First Call?

Walking into your first attorney consultation with these ready saves everyone time:

• Invokana/Invokamet prescription and pharmacy fill records (to establish start and end dates)
• Surgical records and pre/post-op imaging related to the amputation
• ER and hospitalization records for DKA, including ketone and pH lab values
• Documentation of pre-existing diabetic complications (kidney disease, retinopathy, PAD)
• Records showing blood sugar management and weight trends before and after starting the drug

Every state gives patients (or their legal representatives) the right to request copies of their own medical records. Most law firms will send records requests on your behalf if your history is scattered across multiple providers, so incomplete records shouldn’t stop you from having the initial conversation.

---

How Does the Defense Actually Fight These Cases?

Understanding the other side’s playbook tells you a lot about where your own case is strong or weak.

The learned intermediary doctrine. In most states, a drug manufacturer’s duty to warn runs to the prescribing physician, not directly to the patient. Janssen argues its label already disclosed the risks at the time of prescription, and the treating doctor made the final call. Plaintiffs counter that the label simply didn’t contain that risk information before the relevant warning was added — a timing argument, not a doctrine argument.

The “diabetes did it” defense. Type 2 diabetics face elevated amputation risk from vascular disease and neuropathy independent of any specific drug. The defense routinely argues each plaintiff’s amputation was that natural progression, not a drug effect. Countering this requires medical records showing a documented change in vascular status after starting Invokana.

Comparative fault arguments. Smoking history, obesity, and inconsistent blood sugar management get raised to argue for a reduced liability share. This becomes more consequential if a case goes to trial rather than settling, so it’s worth asking your attorney upfront how they plan to handle these arguments.

---

Attorney Fees, and MDL vs. Individual Filing

Nearly every case in this space runs on a contingency fee. No upfront cost, and the firm takes roughly 33–40% of whatever you recover — nothing if there’s no recovery. Case costs (expert witnesses, medical record retrieval, filing fees) are often billed separately, so get the exact percentage and cost treatment in writing before signing.

	Individual lawsuit (state court)	MDL participation (federal, consolidated)
Process	Runs on its own schedule	Shares discovery and expert rulings across cases
Speed	Varies widely by case	Efficient early on; full resolution can still take years
Leverage	Depends heavily on your individual attorney	Influenced by outcomes negotiated by MDL leadership counsel
Best fit	Large or unusual-fact cases	Standard amputation or DKA claims

Which path makes sense depends on your facts. A case with unusual damages or jurisdictional wrinkles sometimes does better filed individually; a standard amputation or DKA claim is generally more efficient run through the MDL. This is a conversation to have explicitly in your first consultation, not something to assume.

---

Choosing an Attorney: What Actually Matters

A firm that runs a lot of TV ads isn’t automatically the right one. Here’s what I’d actually check:

• Mass tort track record. Have they handled Invokana or comparable SGLT2/diabetes drug litigation, not just generic personal injury work?
• Direct representation vs. lead generation. Some firms take your call and then hand your case to another firm entirely. Ask directly whether they litigate the case themselves.
• Expert witness access. Vascular surgery and endocrinology experts are often what wins the causation argument — ask what resources the firm has.
• Fee transparency. Is the percentage (33–40%) and cost deduction method spelled out in the retainer agreement?
• Communication cadence. Will you get regular case status updates, or will you have to chase them?

The same evaluation logic applies whether you’re comparing firms for this case or for related product liability litigation — see our guide on valsartan NDMA cancer lawsuits or the Paragard IUD breakage lawsuit for how attorneys handle similar mass tort structures.

---

Three Mistakes That Sink Otherwise Good Cases

Mistake 1: Waiting to gather records before your first call. Surgical records, hospitalization records, and prescription history dramatically change the quality of an initial consultation. Start the medical records request process before you even schedule a call.

Mistake 2: Assuming your statute of limitations already ran out. Most states apply the discovery rule, starting the clock from when you learned of the injury, not when you started the drug. If your amputation or DKA diagnosis is recent, you may still be eligible even with an old prescription history.

Mistake 3: Signing with a firm that promises a specific dollar amount. No firm can responsibly guarantee a payout before reviewing your records in a mass tort case like this. Prefer firms that explain their evaluation process and fee structure clearly over ones that lead with a number. If you want a broader sense of how attorneys structure fees across personal injury cases generally, our personal injury lawyer fee guide walks through the mechanics in more depth, and our attorney consultation cost guide covers what to expect from that first meeting.

---

Statute of Limitations: Why You Should Check This Today, Not Next Month

Limitations periods vary by state, typically 2–4 years for product liability claims. The critical mechanism is the discovery rule: most states start the clock when you knew or reasonably should have known about the injury, not when you first took Invokana.

This matters most for patients who stopped taking the drug years ago but had an amputation or a related revision surgery recently — those cases likely still have live claims. If your diagnosis was several years back, you may be close to or past the deadline, so don’t sit on it. As with any injury claim involving a delayed or disputed onset date — the same logic applies in cases like hurricane property damage insurance disputes — never calculate your own deadline. Get a lawyer to confirm the actual triggering date for your state and your facts.

---

This article is for informational purposes only and does not constitute legal advice. Eligibility, applicable deadlines, and potential settlement value depend heavily on state law and your individual medical records. If you are considering a claim, consult directly with an attorney experienced in U.S. mass tort and pharmaceutical litigation.